You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國資委指導華潤及國藥集團等藥企全力保醫療物資供應
面對內地新冠肺炎疫情防控新形勢以及人民群眾急劇增加的醫療物資需求,國務院國資委督促指導華潤集團、通用技術集團及國藥集團等涉藥中央企業,全力以赴保障醫療物資供應。三家涉藥中央企業均成立由主要負責同志擔任組長的醫療物資保供領導小組,建立24小時工作機制,企業保持24小時運轉,確保各項保產保供措施落實到位。 其中,華潤醫藥(03320.HK)旗下華潤雙鶴(600062.SH)及華潤三九(000999.SZ)等加大對999小兒氨酚黃那敏顆粒、999感冒靈顆粒、三九強力枇杷露、複方鮮竹瀝液等抗病毒藥品和醫療臨床急需藥品的生產。 通用技術集團所屬中國醫藥部署旗下92間企業建立起覆蓋全國的重點藥品調撥網絡,積極引進新冠病毒治療藥物奈瑪特韋片/利托那韋片,及時滿足民眾用藥需求。 國藥集團部署旗下逾160間醫藥工業企業24小時保供增產。國藥控股(01099.HK)及國藥股份(600511.SH)全員加班加點協調廠家。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account